The company's ₹409 crore IPO got decent attention from big institutional and non-institutional investors, but regular retail folks mostly sat this one out.
Anchor investors chipped in over ₹122 crore before the IPO even opened.
Sai Parenterals plans to use the funds to boost its manufacturing game globally, especially for injectables and oral medicines.